DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Concord Biotech Limited (CONCORDBIO) share price today?

Concord Biotech Limited (CONCORDBIO) is trading at ₹1,339.3 on the NSE, down 1.03% on the day. Source: DocStoX.

What is the PE ratio of Concord Biotech Limited?

Concord Biotech Limited has a price-to-earnings (PE) ratio of 54.0 in the Healthcare sector.

What is the market capitalisation of Concord Biotech Limited?

Concord Biotech Limited has a market capitalisation of approximately ₹14,003 crore.

Is Concord Biotech Limited a profitable company?

Concord Biotech Limited generates a return on equity of 12.9% with a net profit margin of 24.6%. That is a reasonable return on shareholder capital.

What is the 52-week high and low of CONCORDBIO?

Concord Biotech Limited (CONCORDBIO) has traded between ₹987 and ₹1,615 over the past 52 weeks, against a current price of ₹1,339.3.

Does Concord Biotech Limited pay a dividend?

Yes. Concord Biotech Limited currently offers a dividend yield of 0.55%. Dividend payments depend on the board's declaration each year.

Concord Biotech Limited

₹1,339.30▼ -14.00 (-1.03%)

CONCORDBIO·NSE·Healthcare

Market Cap

14003.40 Cr

PE Ratio

54.05

Volume

41,883

Day High - Low

1366.80 - 1332.00

52W High-Low

1615.00 - 987.00

₹1,339.30▼ -14.00 (-1.03%)

Market Cap14003.40 Cr

PE Ratio54.05

Volume41,883

Day High - Low1366.80 - 1332.00

52W High-Low1615.00 - 987.00

Concord Biotech Limited (CONCORDBIO): company summary

The company's annual revenue fell 12.1% to ₹1,055 crore, while annual net profit dropped 30.5% to ₹259 crore.

Concord Biotech Limited (CONCORDBIO) is a small-cap Healthcare company valued at ₹14,003 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move: Concord Biotech Limited last traded at ₹1,339.3, modestly down 1.03% on the day.
Recent developments: On 2026-07-24, the company announced a dividend of ₹7.55 per share, ex-date, reflecting its commitment to shareholder returns. Promoter holding remained at 44.08% as of 2026-06-30, with foreign institutional holding decreasing by 0.28 percentage points and domestic institutional holding increasing by 0.14 percentage points in the quarter.
Financial performance: The company's annual revenue fell 12.1% to ₹1,055 crore, while annual net profit dropped 30.5% to ₹259 crore. However, the latest quarter saw revenue rise 26.2% to ₹257 crore and net profit grow 34.2% to ₹58 crore, indicating a recent improvement in performance.
Valuation multiples: The stock trades at 54.0 times earnings, a premium to the Healthcare median of 32.0, 7.12 times book value. It yields 0.5%.
Things to watch: The company's net profit margin narrowed 6.5 percentage points to 24.6%, and annual net profit declined 30.5%. The stock is 16.6% below its 52-week high, and profit growth has slowed significantly over the past five years, with a 2.0% CAGR in net profit.
Where it stands: Concord Biotech Limited reported a decline in annual net profit and margin, but the latest quarter showed signs of recovery with higher revenue and profit growth. The stock is trading below its 52-week high, and the company remains almost debt-free with a low debt-to-equity ratio.

Summarised by DocStoX's model on 2026-10-03 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.

DocStoX Score

5.1/10

Weak

Fair Value

ROE

12.94%

Average

P/E

54.05x

Expensive

Debt / Equity

0.00

Low

Industry

Healthcare

Pharmaceuticals

Overall View

Mixed

Price performance

NIFTY 500NIFTY SMALLCAP 250

Day₹1332

₹1367

52W₹987.00

₹1615

DocStoX take

Supported by risk (9.4) and quality (7.1), but held back by valuation (0.0). Risk looks strong at 9.4, but that is offset by valuation at 0.0 and growth at 2.8. We are calling it Mixed rather than resolving the conflict for you.

DocStoX score

Low confidence

5.1

/10

Weak

Quality

Solid

ROE 12.9%

Valuation

Expensive

P/E 54.0×

Growth

Flat

Revenue +11.3% 5Y CAGR

Risk

Low risk

D/E 0.00

Momentum

Firm

56% of 52-week range

DocStoX research

Our verdict

Fairly Valued

Fair value not available

Current price

₹1,339

Upside / Downside

—

Implied CAGR

—

Priced in by the market

Uncertainty

—

Est. confidence

At a glance

Market Cap

₹14,003 Cr

52W High / Low

₹1615 / ₹987

Dividend Yield

0.55%

Promoter Holding

44.08%

EPS (TTM)

₹24.78

Book Value

₹192.81

Key highlights

Low leverage — D/E 0.00
Profitable in all of the last 5 years
Healthy net margin (25%)
Valuation is weak (0.0/10)

3 Positives1 Watchout

Growth

Financials

Shareholding

Technicals

Peers

News

Forecasts

About the company

More data

Filings, corporate actions and ownership detail — opened on demand.

More Healthcare stocks · Pharmaceuticals

Explore Concord Biotech Limited’s valuation

Free deep-dive tools · no sign-up

Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.

Concord Biotech Limited peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

Sun Pharmaceutical Industries Limited Divi's Laboratories Limited Torrent Pharmaceuticals Limited Apollo Hospitals Enterprise Limited Zydus Lifesciences Limited Laurus Labs Limited Cipla Limited Dr. Reddy's Laboratories Limited Aurobindo Pharma Limited Mankind Pharma Limited Lupin Limited Manipal Health Enterprises Limited

Compare Concord Biotech Limited with peers

Concord Biotech Limited vs Sun Pharmaceutical Industries Limited Concord Biotech Limited vs Divi's Laboratories Limited Concord Biotech Limited vs Torrent Pharmaceuticals Limited Concord Biotech Limited vs Apollo Hospitals Enterprise Limited Concord Biotech Limited vs Zydus Lifesciences Limited Concord Biotech Limited vs Laurus Labs Limited

Related tools & concepts

Value Concord Biotech Limited with the ratios and calculators DocStoX uses in its analysis.

P/E RatioPrice to earnings Return on Equity (ROE)Profitability ROCECapital efficiency Debt to EquityLeverage P/B RatioPrice to book Net Profit MarginBottom-line efficiency DCF / Intrinsic ValueEstimate fair value CAGR CalculatorAnnualised return Dividend YieldIncome on price Position SizeRisk-based sizing Brokerage CalculatorCharges on a trade SIP CalculatorSystematic investing

Explore further

CONCORDBIO newsLatest coverage & filings Open screenerFilter the whole market